Multiple myeloma (MM) is a cancer of plasma cells that leads to disruption of normal bone marrow function and end organ damage. While still technically considered incurable, life expectancy of multiple myeloma patients has nearly doubled in the past 15 years, and the prognosis for the vast majority of patients, even the elderly, continues to improve. The recent transition of MM from being considered an inevitably fatal malignancy with poor life expectancy to one more characteristic of a chronic disease to be managed has been attributed to the rapid translation of clinical advancements and insights into community practice, and represents one of the greatest clinical success stories in improved cancer treatment and management outcomes today. As a small population cancer, community oncologists who often treat many types of more common malignancies do not see many MM patients and may be challenged to remain current with the latest clinical trial findings that are likely to impact their practice, either immediately, or in the very near future.
Join our Managing Myeloma distinguished team expert and advisory group member Sagar Lonial, MD, at the European Hematology Association (EHA) Annual Meeting 2015, in Vienna Austria, as he discusses the latest clinical findings and insights that are likely to impact multiple myeloma practice today and in the near future with other world-renowned experts including Paul G. Richardson, MD, Antonio Palumbo, MD, and Nikhil Munshi, MD.
Topics of discussion include advances in detecting minimum residual disease and how these may impact practice, the emergence of immunotherapies for MM, the role of carfilzomib-based regimens in relapsed/refractory disease with findings from the ASPIRE and first head-to-head trial of carfilzomib vs bortezomib, the ENDEAVOR trial and optimal dosing schedules of carfilzomib, new targets, next-generation agents and combination strategies including anti-SLAMF7, anti-CD38, and TH-302, and studies that seek to determine cytogenetic markers that predict the risk of progression of MGUS.
Recall recent clinical findings that potentially impact current multiple myeloma treatment and management strategies, or may do so in the near future, throughout the life cycle of the disease.
This activity is eligible for credit through July 20, 2016. After this date, this activity will expire and no further credit will be awarded.
He is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the Journal of Clinical Oncology, Leukemia, and is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and also serves as an invited and ad hoc reviewer for several publications including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others. Dr. Lonial has authored/coauthored over 200 publications and recently was awarded the Celgene ‘Young Investigator’ Award, the MMRF ‘Top 15 Innovator’ Award, and the MMRC ‘Center of the Year’ award.
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Oncology Center, and a hematology/oncology fellowship at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of the American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology, and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Dr. Antonio Palumbo received his medical degree from the University of Torino, Italy, where he served his residency in internal medicine and held a fellowship in hematology/oncology. He is an associate professor of clinical hematology, and director of the Myeloma Unit, Department of Onco-Hematology at University of Torino.
In addition to membership in numerous professional organizations, including the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES), European Society of Medical Oncology (ESMO), European Society of Hematology (EHA), American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), Dr. Palumbo is on the Board of Directors of the International Myeloma Society. He has authored more than 300 publications in peer-reviewed journals as well numerous abstracts and several textbook chapters. Dr. Palumbo specializes in malignant hematology and medical oncology and has clinical and research interest in plasma cell dyscrasia, his current research focuses on the pathogenesis and treatment of multiple myeloma.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-15-044-H01-P. Knowledge-based CPE activity.
Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, Onyx, Sanofi, and Takeda Oncology.
Dr. Nikhil Munshi has received honoraria as a consultant from Celgene Corporation, Merck & Co., Inc., OncoPep, Pfizer Inc., and Takeda Oncology.
Dr. Antonio Palumbo has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Genmab A/S, Janssen Pharmaceuticals, Inc., Onyx, and Takeda Oncology. He has received additional honoraria from Amgen Inc., Bristol-Myers Squibb, Celgene, Genmab, Janssen, Novartis AG, Onyx, Sanofi and Takeda Oncology.
Dr. Paul Richardson has received honoraria related to formal advisory activities from Bristol-Myers Squibb, Celgene Corporation, Genmab A/S, Johnson & Johnson Services, Inc., Novartis AG, Onyx, and Takeda Oncology.
Drs. Lonial, Munshi, Palumbo, and Richardson have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Munshi, Palumbo, and Richardson have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.